Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment

Antag Therapeutics启动了AT-7687的1a期试验，这是一种首创的GIPR拮抗剂，旨在解决肥胖症治疗中的关键空白。

First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity

双盲、安慰剂对照试验中，首次对健康瘦型受试者和肥胖受试者评估AT-7687的安全性、耐受性、药代动力学和代谢效应进行给药。

With strong genetic and clinical validation, AT-7687 aims to induce weight loss without gastrointestinal side effects, a major challenge in obesity management

凭借强大的遗传和临床验证，AT-7687旨在诱导减重的同时避免胃肠道副作用，这是肥胖管理中的主要挑战。

Copenhagen, Denmark, 2 April 2025 –

丹麦哥本哈根，2025年4月2日 –

Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the initiation of its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist.

Antag Therapeutics（“Antag”或“公司”），一家致力于开发肥胖症创新疗法的生物制药公司，今日宣布启动其首次人体Phase 1临床试验，评估AT-7687——一种首创的葡萄糖依赖性促胰岛素多肽受体（GIPR）拮抗剂。

AT-7687 is designed to offer a new approach to obesity treatment by targeting the GIPR, a mechanism with strong genetic and clinical validation for its potential to improve weight loss efficacy and tolerability of incretin-based therapies..

AT-7687 旨在通过靶向 GIPR 提供一种治疗肥胖的新方法，这一机制具有强大的遗传学和临床验证，有望提高减重效果及基于肠促胰岛素疗法的耐受性。

Despite recent advances in obesity treatment, a substantial number of patients are unable to reach their weight loss targets on existing therapies, in addition to struggling with gastrointestinal side effects such as nausea and vomiting. Clinical studies indicate that these side effects are a leading cause of treatment discontinuation,.

尽管肥胖症治疗领域近期取得了进展，但仍有大量患者无法通过现有疗法达到减重目标，此外还饱受恶心和呕吐等胃肠道副作用的困扰。临床研究表明，这些副作用是导致治疗中断的主要原因。

1

1

limiting the long-term health benefits of therapy – such as cardiovascular risk reduction – and ultimately leaving many people living with obesity without effective, sustainable treatment options. AT-7687 is uniquely designed to address these challenges by offering a targeted, well-tolerated obesity treatment, either as a monotherapy or in combination with other treatments such as the GLP-1 and amylin-based therapies.

限制了治疗的长期健康益处——如降低心血管风险——并最终使许多肥胖患者缺乏有效且可持续的治疗选择。AT-7687 的独特设计旨在通过提供一种针对性强、耐受性良好的肥胖治疗方法来应对这些挑战，既可以作为单一疗法，也可与 GLP-1 和基于淀粉样蛋白的疗法等其他治疗方式联合使用。

Moreover, AT-7687 has the potential to deliver additional cardiometabolic benefits such as improved glycemic control and body composition..

此外，AT-7687还有可能带来额外的心脏代谢益处，例如改善血糖控制和身体组成。

The Phase 1a trial is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of AT-7687. It will be conducted in healthy lean and healthy subjects living with obesity, with topline results expected in Q4 2025.

1a期试验是一项双盲、随机、安慰剂对照研究，旨在评估AT-7687的安全性、耐受性和药代动力学。试验将在健康的瘦型个体和健康肥胖受试者中进行，预计在2025年第四季度获得初步结果。

Following this study, the Company plans to investigate AT-7687 as a combination therapy in patients treated with a GLP-1 receptor agonist, with the study expected to commence at the end of 2025.

基于这项研究，该公司计划在使用GLP-1受体激动剂治疗的患者中，将AT-7687作为联合疗法进行研究，预计该研究将于2025年底开始。

Jörg Möller, Chief Executive Officer of Antag Therapeutics, commented:

安塔格治疗公司的首席执行官约尔格·莫勒评论道：

“

“

The initiation of this Phase 1 trial represents a pivotal milestone for Antag and in advancing the chronic weight management paradigm for people living with obesity. While GLP-1-based therapies have transformed treatment options, many patients continue to face challenges with tolerability and long-term adherence.

这项 1 期试验的启动代表了 Antag 的一个关键里程碑，并推动了肥胖症患者的慢性体重管理模式的发展。尽管基于 GLP-1 的疗法已经改变了治疗选择，但许多患者仍然面临耐受性和长期依从性的挑战。

AT-7687 is uniquely designed to address these gaps, with remarkable potential both as a standalone therapy and as a powerful complement that may be flexibly combined with existing and future treatment options for more individualized therapy. By leveraging a novel mechanism of action, AT-7687 aims to deliver not only sustained and healthier weight loss, but comprehensive long-term benefits across a range of indications.”.

AT-7687 的独特设计旨在弥补这些空白，它不仅作为单一疗法具有显著潜力，而且作为一种强大的补充，可以灵活地与现有和未来的治疗方案相结合，实现更加个性化的治疗。通过利用一种新颖的作用机制，AT-7687 旨在不仅实现持久且健康的体重减轻，还能在一系列适应症中带来全面的长期益处。”

Richard Nkulikiyinka, Chief Medical Officer of Antag Therapeutics, added:

安塔格治疗公司的首席医疗官理查德·恩库利基因加补充道：

“AT-7687’s mechanism targets key metabolic pathways that influence not only weight loss and maintenance, but also broader cardiometabolic health. By improving tolerability and addressing underlying metabolic drivers, AT-7687 has the potential for more sustainable and clinically meaningful outcomes in a much broader patient population than served by currently approved therapies.

“AT-7687 的作用机制针对影响体重减轻和维持以及更广泛的心脏代谢健康的关键代谢途径。通过提高耐受性并解决潜在的代谢驱动因素，AT-7687 有潜力在比目前获批疗法所覆盖的更为广泛的患者群体中实现更可持续且具有临床意义的结果。”

This Phase 1 trial will provide essential insights into how GIPR antagonism can enhance the current treatment paradigm.”.

这项 1 期试验将提供有关 GIPR 拮抗如何增强当前治疗模式的重要见解。

AT-7687 has demonstrated potential in preclinical models, achieving a profound body weight reduction in non-human primates over six weeks. Notably, when combined with a GLP-1 agonist, its weight loss effects were enhanced, suggesting a synergistic benefit for patients requiring combination therapy. Additionally, AT-7687 has shown excellent tolerability, with substantially lower gastrointestinal side effects than existing therapies, potentially improving long-term adherence and treatment outcomes..

AT-7687在临床前模型中展示了潜力，在非人灵长类动物中六周内实现了显著的体重减轻。值得注意的是，当与GLP-1激动剂联合使用时，其减重效果得到增强，表明对需要联合治疗的患者具有协同效益。此外，AT-7687表现出极佳的耐受性，胃肠道副作用明显低于现有疗法，可能改善长期依从性和治疗效果。

-ENDS-

-结束-

About Antag Therapeutics

关于Antag Therapeutics

Antag Therapeutics is a biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs.

Antag Therapeutics是一家生物制药公司，致力于通过GIP受体拮抗作用发现和开发针对肥胖症和心代谢疾病的新型疗法。作为探索GIP受体拮抗剂潜力的先驱，该公司专注于推动科学发展，通过提供突破性的解决方案来满足未被满足的医疗需求，从而改善患者预后。

For more information, please visit .

如需更多信息，请访问 。

https://antagtherapeutics.com

https://antagtherapeutics.com

.

。

About AT-7687

关于AT-7687

The development of AT-7687 builds on the groundbreaking discovery of an endogenous GIPR antagonist by Professors Jens Holst, renowned for his discovery of GLP-1, and Mette Rosenkilde. In addition to promising preclinical data, the therapeutic potential of AT-7687 is further supported by robust human genetic validation, demonstrating that reducing GIP receptor activity is associated with leanness..

AT-7687 的开发基于 Jens Holst 教授（以发现 GLP-1 闻名）和 Mette Rosenkilde 教授在内源性 GIPR 拮抗剂方面的突破性发现。除了令人鼓舞的临床前数据外，AT-7687 的治疗潜力还得到了强有力的人类遗传学验证的支持，证明降低 GIP 受体活性与瘦体质相关。

Contacts

联系人

Antag Therapeutics

安塔格治疗公司

Joerg Moeller, MD, PhD

约尔格·穆勒，医学博士，哲学博士

CEO, Antag Therapeutics

首席执行官，Antag Therapeutics公司

Email:

电子邮件：

antag@antagtherapeutics.com

antag@antagtherapeutics.com

Antag Therapeutics

安塔格治疗公司

Media Contacts

媒体联系人

ICR Healthcare

ICR医疗保健

Davide Salvi, Lucy Featherstone

戴维德·萨尔维，露西·费瑟斯通

Email:

电子邮件：

antagtx@icrhealthcare.com

antagtx@icrhealthcare.com